Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2013 08:00 ET | Source: Arno Therapeutics Inc.

Arno Therapeutics Completes $30.7 Million Financing, Recapitalization and 1-for-8 Reverse Stock Split

– All Outstanding Convertible Debentures Converted into Common Stock – – Funds to be Used for Continued Clinical Development of Lead Candidate, Onapristone –...
October 29, 2013 17:00 ET | Source: Arno Therapeutics Inc.

Arno Therapeutics Data Supports Further Evaluation of Onapristone in Prostate Cancer

FLEMINGTON, N.J., Oct. 29, 2013 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
September 28, 2013 08:00 ET | Source: Arno Therapeutics Inc.

Arno Therapeutics to Present Data Validating Target Biomarker at European Cancer Congress 2013

Poster Session: Diagnostics/Biomarkers, Hall 4 Abstract #1001; Poster #258 Abstract #1002; Poster #274 - Underscores role of anti-progestins - - Supports further evaluation of onapristone and...
September 09, 2013 08:00 ET | Source: Arno Therapeutics Inc.

Arno Therapeutics Submits IMPD to French Health Authority to Initiate Phase I Trial of Onapristone in PR Positive Tumors

FLEMINGTON, N.J., Sept. 9, 2013 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
August 21, 2013 09:06 ET | Source: Arno Therapeutics Inc.

Arno Therapeutics Initiates Pharmacokinetic Study for Onapristone Following Regulatory Acceptance

FLEMINGTON, N.J., Aug. 21, 2013 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
June 03, 2013 08:00 ET | Source: Arno Therapeutics Inc.

Arno Therapeutics to Collaborate With Veridex on Development of Diagnostic Test

FLEMINGTON, N.J., June 3, 2013 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced...
May 10, 2013 08:00 ET | Source: Arno Therapeutics Inc.

Arno Therapeutics to Collaborate With Clarient for Development of Diagnostic Test

FLEMINGTON, N.J., May 10, 2013 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced...
April 08, 2013 13:00 ET | Source: Arno Therapeutics Inc.

Arno Therapeutics Reports Activated Progesterone Receptors Predictive of Response to Onapristone

FLEMINGTON, N.J., April 8, 2013 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
March 19, 2013 08:30 ET | Source: Arno Therapeutics Inc.

Arno Therapeutics Engages The Ruth Group for Investor Relations and Public Relations Counsel

FLEMINGTON, N.J., March 19, 2013 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCBB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...